Table 2 Anti-tumor activity assessed by RECIST v1.1.
Efficacy | Cohort A (N = 18) | Cohort B (N = 10) |
|---|---|---|
ORR, N (%) [90% CI] | 2 (11%) [4–29] | 0 (0%) [0–21] |
DCR, N (%) [90% CI] | 7 (39%) [23–58] | 0 (0%) [0–21] |
Best overall response, N (%) | ||
Complete response | 0 (0%) | 0 (0%) |
Partial response | 2 (11%) | 0 (0%) |
Stable disease | 5 (28%) | 0 (0%) |
Progressive disease | 10 (55%) | 7 (70%) |
Could not be evaluated/assessed | 1 (6%) | 3 (30%) |
